Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SU011248; Capecitabine · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SU011248; Capecitabine | DRUG | Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity. |
Inclusion Criteria: * Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists * Patient has good performance status (ECOG 0 or 1) Exclusion Criteria: * Prior treatment with either SU011248 or capecitabine. * Hypertension that c...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
SU011248 and Capecitabine is an investigational combination of two small molecule drugs being studied for the treatment of solid tumors, including breast cancer and other neoplasms. The combination is in Phase 1 clinical development and is not yet approved by regulatory authorities.
SU011248 and Capecitabine is being developed by Pfizer, Inc., a biopharmaceutical company publicly traded under the ticker symbol PFE on the New York Stock Exchange. The company is conducting clinical research to evaluate the safety and tolerability of this drug combination.
SU011248 and Capecitabine is in Phase 1 clinical development. This early-stage trial is designed to determine the best doses of the two drugs when administered together. The drug combination is investigational and has not been approved for any indication.
SU011248 and Capecitabine has one completed Phase 1 clinical trial registered as NCT00618124, titled 'A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together.' The trial enrolled 77 participants in the United States and was not randomized or blinded.
SU011248 is also known as sunitinib, a small molecule tyrosine kinase inhibitor. In the clinical trial NCT00618124, SU011248 is administered in combination with capecitabine, another chemotherapy drug, to evaluate their combined use in treating solid tumors.